The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

Visvanathan, Sudha; Wagner, Carrie; Marini, Joseph C.; Lovell, Daniel J.; Martini, Alberto; Petty, Ross; Cuttica, Ruben; Woo, Patricia; Espada, Graciela; Gattorno, Marco; Apaz, Maria T.; Baildam, Eileen; Fasth, Anders; Gerloni, Valeria; Lahdenne, Pekka; Quartier, Pierre; Saurenmann, Rotraud; Travers, Suzanne; Mendelsohn, Alan; Xu, Stephen
January 2010
Pediatric Rheumatology;2010, Vol. 8, p24
Academic Journal
Background: We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic arthritis (JIA). Methods: In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg + methotrexate (MTX)(n = 60) or placebo + MTX (n = 62) at weeks 0, 2, and 6. At week 14, patients receiving placebo + MTX crossed over to infliximab 6 mg/kg + MTX; patients receiving infliximab 3 mg/kg + MTX continued treatment through week 44. Sera and plasma from eligible patients receiving infliximab 3 mg/kg + MTX (n = 34) and receiving placebo→infliximab 6 mg/kg +MTX (n = 38) were collected at weeks 0, 2, 14, 16, 28, and 52 and analyzed for inflammatory markers (IL-6, IL-12p40, ICAM-1, MMP-3, VEGF, TNF-α, and CRP). Results: At week 2, decreases from baseline in IL-6, ICAM-1, MMP-3, TNF-α, and CRP were greater with infliximab versus placebo treatment, and with the exception of CRP, these differences were generally maintained through week 14. The decreases from baseline to week 52 in IL-6, ICAM-1, VEGF, MMP-3, and CRP and increases in IL-12p40 levels were larger in patients receiving placebo→infliximab 6 mg/kg +MTX versus infliximab 3 mg/kg + MTX treatment. Patients receiving infliximab 3 mg/kg+MTX who achieved an American College of Rheumatology Pediatric 30 (ACR-Pedi-30) response had significantly larger decreases from baseline in ICAM-1 (p = 0.0105) and MMP-3 (p = 0.0253) at week 2 and in ICAM-1 (p = 0.0304), MMP-3 (p = 0.0091), and CRP (p = 0.0011) at week 14 versus ACR-Pedi-30 nonresponders. Conclusion: Infliximab + MTX attenuated several inflammatory markers in patients with JIA; larger decreases in ICAM-1, MMP-3, and CRP levels were observed in ACR-Pedi-30 responders versus nonresponders. Trial Registration: NCT00036374


Related Articles

  • PEDIATRIC RHEUMATOLOGY.  // Current Medical Literature: Rheumatology;2005, Vol. 24 Issue 2, p47 

    This article focuses on various studies related to pediatric rheumatology. One study is "Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibodies in Juvenile Idiopathic Arthritis," by O. Kasapcopur, S. Altun and M. Aslan. The primary objective of the present study was to correlate...

  • Methotrexate in Rheumatoid Arthritis. Tugwell, Peter; Bennett, Kathryn; Gent, Michael // Annals of Internal Medicine;Sep87, Vol. 107 Issue 3, p358 

    Reviews the evidence on the safety and efficacy of methotrexate as a second- or third-line agent for treating patients with rheumatoid arthritis. Placebo-controlled Clinical trials; Description of methotrexate; Employment of meta-analysis methods.

  • Adherence to methotrexate in juvenile idiopathic arthritis. Pelajo, Christina; Sgarlat, Caitlin; Lopez-Benitez, Jorge; Oliveira, Sheila; Rodrigues, Marta; Sztajnbok, Flavio; Diniz, Christianne; Miller, Laurie // Rheumatology International;Feb2012, Vol. 32 Issue 2, p497 

    Non-adherence to treatments for chronic diseases may jeopardize patients' health, increase costs of care, and cause unnecessary clinic appointments and diagnostic studies, as well as additional treatments with potentially serious side effects. Little is known about adherence to methotrexate in...

  • Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. Kremer, Joel M.; Genant, Harry K.; Moreland, Larry W.; Russell, Anthony S.; Emery, Paul; Abud-Mendoza, Carlos; Szechinski, Jacek; Li, Tracy; Ge, Zhiyu; Becker, Jean-Claude; Westhovens, Rene // Annals of Internal Medicine;6/20/2006, Vol. 144 Issue 12, p865 

    Background: The selective co-stimulation modulator abatacept demonstrated efficacy for treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of abatacept in patients with persistent, active rheumatoid arthritis despite methotrexate treatment. Design:...

  • Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Takeuchi, Tsutomu; Matsubara, Tsukasa; Nitobe, Taisuke; Suematsu, Eiichi; Ohta, Syuji; Honjo, Shigeru; Abe, Tohru; Yamamoto, Ami; Miyasaka, Nobuyuki // Modern Rheumatology (Springer Science & Business Media B.V.);Mar2013, Vol. 23 Issue 2, p226 

    Objective: The objective of this study was to assess the response to abatacept at doses of 2 mg/kg and 10 mg/kg compared to placebo in patients with active rheumatoid arthritis (RA) with an inadequate clinical response to methotrexate (MTX). Methods: In this multicenter, placebo-controlled,...

  • THE BIOMARKERS USED FOR DIAGNOSIS AND ASSESSMENT OF RHEUMATOID ARTHRITIS. Filipescu, Ileana Cosmina; Rednic, Simona // Romanian Journal of Rheumatology;2014, Vol. 23 Issue 1, p5 

    Significant progress in the pathogenesis, assessment and treatment of rheumatoid arthristis has been made after 1920, the year when the most frequently used remissive agents, methotrexate was introduced. The clinical and biological assessment is the "cornerstone" of monitoring any patient with...

  • Abatacept + methotrexate improves HRQOL in RA.  // PharmacoEconomics & Outcomes News;4/8/2006, Issue 500, p23 

    Abatacept plus methotrexate significantly improves health-related (HR) QOL, compared with methotrexate monotherapy, in patients with rheumatoid arthritis (RA) who have had an inadequate response to methotrexate, according to the results of a study presented at the 2nd Asia-Pacific International...

  • La era dorada del tratamiento de la artritis reumatoide. Mercado, Ulises // Revista Medica del IMSS;mar/abr2014, Vol. 52 Issue 2, p126 

    Today, we enjoy the golden age of rheumatology. In the 1970s, the paradigm for treating rheumatoid arthritis consisted in a pyramid. In the decade of the 1980s, and shortly after began a revolution in the understanding and treatment of rheumatic diseases. Methotrexate and tumor necrosis...

  • Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Tanaka, Eiichi; Inoue, Eisuke; Kawaguchi, Yasushi; Tomatsu, Taisuke; Yamanaka, Hisashi; Hara, Masako; Kamatani, Naoyuki // Modern Rheumatology;Aug2006, Vol. 16 Issue 4, p214 

    This report documents the results of a study performed to examine clinical use of mizoribine (MZR), using data from a large-scale prospective cohort study, IORRA (Institute of Rheumatology Rheumatoid Arthritis). The number of patients with RA entered in this study from October 2000 through...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics